TY - JOUR
T1 - Viperin restricts Zika virus and tick-borne encephalitis virus replication by targeting NS3 for proteasomal degradation
AU - Panayiotou, Christakis
AU - Lindqvist, Richard
AU - Kurhade, Chaitanya
AU - Vonderstein, Kirstin
AU - Pasto, Jenny
AU - Edlund, Karin
AU - Upadhyay, Arunkumar S.
AU - Överby, Anna K.
N1 - Funding Information:
This work was supported by the Kempe Foundations, the Laboratory for Molecular Medicine Sweden (MIMS), the Umeå Center for Microbial Research (UCMR), Linneus Support, the Swedish Research Council (VR) (2011-2795, 2017-02438), the Swedish Foundation for Strategic Research (SSF) (ICA10-0059, FFL12-0089), and Västerbotten County Hospital (A.K.Ö.). The funding bodies had no role in study design, data collection or interpretation, or the decision to submit the work for publication.
Funding Information:
We thank Gerhard Dobler of the Bundeswehr Institute of Microbiology (Munich, Germany) for providing TBEV (strain Hypr) and ZIKV (strain MR766), S. Vene (Folkhälsoinstitutet, Stockholm, Sweden) for providing JEV (strain Nakayama), and M. Niedrig (Robert Koch Institute, Berlin, Germany) for providing YFV (strain Asibi) and the anti-TBEV E antibody. We are also grateful to the Biochemical Imaging Center, Umeå (BICU), part of the National Microscopy Infrastructure (NMI), for outstanding imaging support. This work was supported by the Kempe Foundations, the Laboratory for Molecular Medicine Sweden (MIMS), the Umeå Center for Microbial Research (UCMR), Linneus Support, the Swedish Research Council (VR) (2011-2795, 2017-02438), the Swedish Foundation for Strategic Research (SSF) (ICA10-0059, FFL12-0089), and Västerbotten County Hospital (A.K.ö.). The funding bodies had no role in study design, data collection or interpretation, or the decision to submit the work for publication. C.P., R.L., C.K., K.V., J.P., K.E., and A.S.U. designed, performed, and evaluated the experiments. C.P. and R.L. wrote the manuscript; R.L. prepared the figures; and A.K.ö. designed experiments and interpreted the data, wrote the manuscript, and provided funding. All authors analyzed the results. We declare that we have no conflicts of interests
Publisher Copyright:
© 2018 American Society for Microbiology.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Flaviviruses are arthropod-borne viruses that constitute a major global health problem, with millions of human infections annually. Their pathogenesis ranges from mild illness to severe manifestations such as hemorrhagic fever and fatal encephalitis. Type I interferons (IFNs) are induced in response to viral infection and stimulate the expression of interferon-stimulated genes (ISGs), including that encoding viperin (virusinhibitory protein, endoplasmic reticulum associated, IFN inducible), which shows antiviral activity against a broad spectrum of viruses, including several flaviviruses. Here we describe a novel antiviral mechanism employed by viperin against two prominent flaviviruses, tick-borne encephalitis virus (TBEV) and Zika virus (ZIKV). Viperin was found to interact and colocalize with the structural proteins premembrane (prM) and envelope (E) of TBEV, as well as with nonstructural (NS) proteins NS2A, NS2B, and NS3. Interestingly, viperin expression reduced the NS3 protein level, and the stability of the other interacting viral proteins, but only in the presence of NS3. We also found that although viperin interacted with NS3 of mosquito-borne flaviviruses (ZIKV, Japanese encephalitis virus, and yellow fever virus), only ZIKV was sensitive to the antiviral effect of viperin. This sensitivity correlated with viperin's ability to induce proteasome-dependent degradation of NS3. ZIKV and TBEV replication was rescued completely when NS3 was overexpressed, suggesting that the viral NS3 is the specific target of viperin. In summary, we present here a novel antiviral mechanism of viperin that is selective for specific viruses in the genus Flavivirus, affording the possible availability of new drug targets that can be used for therapeutic intervention.
AB - Flaviviruses are arthropod-borne viruses that constitute a major global health problem, with millions of human infections annually. Their pathogenesis ranges from mild illness to severe manifestations such as hemorrhagic fever and fatal encephalitis. Type I interferons (IFNs) are induced in response to viral infection and stimulate the expression of interferon-stimulated genes (ISGs), including that encoding viperin (virusinhibitory protein, endoplasmic reticulum associated, IFN inducible), which shows antiviral activity against a broad spectrum of viruses, including several flaviviruses. Here we describe a novel antiviral mechanism employed by viperin against two prominent flaviviruses, tick-borne encephalitis virus (TBEV) and Zika virus (ZIKV). Viperin was found to interact and colocalize with the structural proteins premembrane (prM) and envelope (E) of TBEV, as well as with nonstructural (NS) proteins NS2A, NS2B, and NS3. Interestingly, viperin expression reduced the NS3 protein level, and the stability of the other interacting viral proteins, but only in the presence of NS3. We also found that although viperin interacted with NS3 of mosquito-borne flaviviruses (ZIKV, Japanese encephalitis virus, and yellow fever virus), only ZIKV was sensitive to the antiviral effect of viperin. This sensitivity correlated with viperin's ability to induce proteasome-dependent degradation of NS3. ZIKV and TBEV replication was rescued completely when NS3 was overexpressed, suggesting that the viral NS3 is the specific target of viperin. In summary, we present here a novel antiviral mechanism of viperin that is selective for specific viruses in the genus Flavivirus, affording the possible availability of new drug targets that can be used for therapeutic intervention.
KW - Flavivirus
KW - Interferons
KW - ISG
KW - NS3
KW - Proteasomal degradation
KW - Viperin
UR - http://www.scopus.com/inward/record.url?scp=85043772814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043772814&partnerID=8YFLogxK
U2 - 10.1128/JVI.02054-17
DO - 10.1128/JVI.02054-17
M3 - Article
C2 - 29321318
AN - SCOPUS:85043772814
SN - 0022-538X
VL - 92
JO - Journal of Virology
JF - Journal of Virology
IS - 7
M1 - e02054-17
ER -